DDB2

Summary

DDB2 (damage specific DNA binding protein 2, HGNC:2718) is a protein-coding gene on chromosome 11p11.2, encoding DNA damage-binding protein 2 (Q92466). Protein, which is both involved in DNA repair and protein ubiquitination, as part of the UV-DDB complex and DCX (DDB1-CUL4-X-box) complexes, respectively.

This gene encodes a protein that is necessary for the repair of ultraviolet light-damaged DNA. This protein is the smaller subunit of a heterodimeric protein complex that participates in nucleotide excision repair, and this complex mediates the ubiquitylation of histones H3 and H4, which facilitates the cellular response to DNA damage. This subunit appears to be required for DNA binding. Mutations in this gene cause xeroderma pigmentosum complementation group E, a recessive disease that is characterized by an increased sensitivity to UV light and a high predisposition for skin cancer development, in some cases accompanied by neurological abnormalities. Two transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 1643 — RefSeq curated summary.

At a glance

• Gene–disease (curated): xeroderma pigmentosum group E (Definitive, ClinGen) — +1 more curated relationship
• GWAS associations: 12
• Clinical variants (ClinVar): 174 total — 9 pathogenic, 5 likely-pathogenic
• Phenotypes (HPO): 64
• Cancer driver (intOGen): activating (oncogene-like) across 2 cancer types
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity no evidence
• MANE Select transcript: NM_000107

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2718
Approved symbol	DDB2
Name	damage specific DNA binding protein 2
Location	11p11.2
Locus type	gene with protein product
Status	Approved
Aliases	DDBB, UV-DDB2, FLJ34321, XPE
Ensembl gene	ENSG00000134574
Ensembl biotype	protein_coding
OMIM	600811
Entrez	1643

Gene structure

Transcript identifiers

Ensembl transcripts: 27 — 17 protein_coding, 5 retained_intron, 4 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000256996, ENST00000378600, ENST00000378601, ENST00000378603, ENST00000610805, ENST00000612309, ENST00000614394, ENST00000614825, ENST00000614884, ENST00000615695, ENST00000616278, ENST00000617022, ENST00000617847, ENST00000620515, ENST00000622090, ENST00000622878, ENST00000896514, ENST00000896515, ENST00000896516, ENST00000915750, ENST00000915751, ENST00000915752, ENST00000915753, ENST00000967663, ENST00000967664, ENST00000967665, ENST00000967666

RefSeq mRNA: 6 — MANE Select: NM_000107 NM_000107, NM_001300734, NM_001399874, NM_001399875, NM_001399876, NM_001399878

CCDS: CCDS73284, CCDS7927, CCDS91469

Canonical transcript exons

ENST00000256996 — 10 exons

Exon	Start	End
ENSE00000839238	47234573	47234672
ENSE00000839239	47234757	47234934
ENSE00000989101	47232814	47232959
ENSE00001098002	47214974	47215263
ENSE00001098005	47216336	47216472
ENSE00001180944	47216858	47217049
ENSE00003485154	47235270	47235412
ENSE00003570899	47238800	47239217
ENSE00003649546	47237837	47238001
ENSE00003675133	47238138	47238183

Expression profiles

Bgee: expression breadth ubiquitous, 235 present calls, max score 96.65.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 34.3030 / max 291.9871, expressed in 1809 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
114167	17.2636	1697
114166	14.6598	1787
114165	1.8025	973
114168	0.4617	194
114169	0.0801	22
114170	0.0353	11

Top tissues by expression

277 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skin of abdomen	UBERON:0001416	96.65	gold quality
skin of leg	UBERON:0001511	96.60	gold quality
right uterine tube	UBERON:0001302	96.44	gold quality
right adrenal gland cortex	UBERON:0035827	96.13	gold quality
right adrenal gland	UBERON:0001233	95.48	gold quality
descending thoracic aorta	UBERON:0002345	95.12	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	94.98	gold quality
zone of skin	UBERON:0000014	94.74	gold quality
granulocyte	CL:0000094	94.61	gold quality
left adrenal gland	UBERON:0001234	94.52	gold quality
ascending aorta	UBERON:0001496	94.49	gold quality
thoracic aorta	UBERON:0001515	94.44	gold quality
left adrenal gland cortex	UBERON:0035825	94.31	gold quality
tibial nerve	UBERON:0001323	93.72	gold quality
esophagus mucosa	UBERON:0002469	93.71	gold quality
endometrium epithelium	UBERON:0004811	93.64	gold quality
vagina	UBERON:0000996	93.57	gold quality
minor salivary gland	UBERON:0001830	93.52	gold quality
muscle layer of sigmoid colon	UBERON:0035805	93.38	gold quality
lower esophagus mucosa	UBERON:0035834	93.35	gold quality
ectocervix	UBERON:0012249	93.20	gold quality
apex of heart	UBERON:0002098	93.17	gold quality
body of pancreas	UBERON:0001150	93.16	gold quality
body of uterus	UBERON:0009853	92.96	gold quality
esophagus	UBERON:0001043	92.94	gold quality
right lobe of liver	UBERON:0001114	92.75	gold quality
adrenal gland	UBERON:0002369	92.71	gold quality
aorta	UBERON:0000947	92.62	gold quality
endocervix	UBERON:0000458	92.55	gold quality
rectum	UBERON:0001052	92.53	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.66

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

3 targets.

Target	Regulation
BCL2	Repression
SOD2	Repression
XPA	Unknown

Upstream regulators (CollecTRI, top): BRCA1, E2F1, E2F3, NF1, SP1, TP53, TP63

miRNA regulators (miRDB)

16 targeting DDB2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-3612	99.45	66.02	1333
HSA-MIR-650	99.45	65.77	1309
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-1286	99.09	66.23	1046
HSA-MIR-3150B-3P	98.81	67.21	1728
HSA-MIR-218-1-3P	98.63	67.97	832
HSA-MIR-6728-3P	98.63	67.63	1534
HSA-MIR-3187-3P	97.38	65.80	904
HSA-MIR-1291	96.28	65.89	1224
HSA-MIR-6813-3P	95.78	63.78	540
HSA-MIR-6775-3P	95.76	65.91	982
HSA-MIR-6851-3P	95.73	65.11	688
HSA-MIR-328-3P	92.82	64.37	521

Functional genomics

ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• These results indicate that DDB2 is a modulator of UV-induced apoptosis, and that UV resistance can be overcome by inhibition of DDB2 (PMID:11852074)
• These results demonstrate direct activation of the human DDB2 gene by p53. The corresponding region in the mouse DDB2 gene shared significant sequence identity with the human gene but was deficient for p53 binding and transcriptional activation. (PMID:11971958)
• Sequential binding of UV DNA damage binding factor and degradation of the p48 subunit as early events after UV irradiation (PMID:12034848)
• findings substantiate the physical and functional connection between the hepatitis B virus X protein and the DDB1-DDB2 heterodimer, leading to the regulation of the pool of the viral protein (PMID:12050362)
• These findings indicate that hepatitis B virus X protein acts through a pathway that involves a DDB2-independent nuclear function of DDB1 and that this activity will depend on the relative concentration of DDB1 and DDB2 in cells. (PMID:12151405)
• BRCA1 upregulates DDB2, with some evidence that p53 is involved in its regulation. (PMID:12496474)
• overexpression of DDB2 in V79 cell potentiates DNA repair and protects cells from UV-induced apoptosis and cytotoxicity. (PMID:12553360)
• DDB2 and CSA are each integrated into nearly identical complexes via interaction with DDB1 (PMID:12732143)
• DDB2p48 activates the recruitment of XPC to cyclobutane pyrimidine dimers and may be the initial recognition factor in the nucleotide excision repair pathway (PMID:12944386)
• Data suggest that both before and after UV irradiation, DDB2 directly regulates p53 levels, while DDB2 expression is itself regulated by p53. (PMID:14560002)
• identification of four DDB2 variants from HeLa cells (D1-D4) that are generated by alternative splicing (PMID:14751237)
• DDB2 regulates TNF signaling-mediated apoptosis via cFLIP and contributes to acquired cross-resistance. (PMID:15644494)
• UV-DDB interacts with XPC physically, and both are polyubiquitylated by the UV-DDB-ubiquitin ligase complex. (PMID:15882621)
• DDB1-DDB2 protein complex recognizes DNA mismatches and lesions (PMID:16223728)
• DDB2 has an intrinsic damaged DNA binding activity (PMID:16260596)
• Monoubiquitinated histone H2A in native chromatin coimmunoprecipitates with the endogenous DDB1-CUL4A(DDB2) complex in response to UV irradiation. (PMID:16473935)
• CUL-4A mediates the proteolytic degradation of DDB2 and this degradation event, initiated at the lesion sites, regulates damage recognition by XPC. (PMID:16527807)
• DDB2 can bind to damaged DNA in vivo as a monomer, whereas Cul4A recruitment to damage sites depends on the fully assembled complex. (PMID:16951172)
• Results suggest that the roles of p53 and nucleotide excision repair in the recovery from UV-induced replication are separable and DDB2-independent. (PMID:17630510)
• A nonsense mutation 574CT (R192X) in DDB2 was found in association facial neoplasms in a form of xeroderma pigmentosum.The parents were heterozygous & the patient homozygous. (PMID:17660462)
• provide genetic evidence linking the regulation of p21(Waf1/Cip1) to the nucleotide excision repair activity of DDB2 (PMID:17967871)
• p53 determines the switch by regulating ddb2 and DNA double-strand breaks in antineoplastic agent treatment of glioblastoma multiforme. (PMID:18089819)
• These findings demonstrate for the first time that DDB2 can play a role as oncogene and may become a promising candidate as a predictive marker in breast cancer. (PMID:18431487)
• DDB1-CUL4B(DDB2) E3 ligase may have a distinctive function in modifying the chromatin structure at the site of UV lesions to promote efficient NER. (PMID:18593899)
• p38 MAPK regulates chromatin remodeling as well as DDB2 degradation for facilitating NER factor assembly (PMID:18806262)
• Results suggest a model in which UV-dependent degradation of DDB2 is important for the release of DDB1 from continuous association to unrepaired DNA and makes DDB1 available for its other DNA damage response functions. (PMID:18936169)
• The structure DDB1-DDB2 complex shows the tightly localized probing of the photolesions, combined with proofreading in the photodimer pocket, enables DDB2 to detect lesions refractory to detection by other damage surveillance proteins. (PMID:19109893)
• DDB2 exerts, at least in part, a control of breast cancer cell growth through its negative regulation of constitutive expression of the SOD2 gene. (PMID:19339246)
• p53 is primarily protective against ultraviolet rays-induced apoptosis in primary human fibroblasts and this activity of p53 does not require DDB2. (PMID:19428372)
• Results provide evidence for a new regulatory loop involving the NER protein DDB2, Mdm2, and p21(Waf1/Cip1) that is critical in deciding cell fate (apoptosis or arrest) upon DNA damage. (PMID:19541625)
• Overexpression of DDB2 enhances the sensitivity of ovarian cancer cells to cisplatin by augmenting cellular apoptosis. (PMID:20013802)
• Data show that XPC and Ku oppositely regulate the ubiquitin ligase activity of DDB2, and that DDB2 complex-mediated ubiquitylation plays a role in recruiting XPA to damaged sites. (PMID:20368362)
• Damaged DNA-binding protein 2 (DDB2) protects against UV irradiation in human cells and Drosophila (PMID:20398405)
• Multiple skin cancers in adults are associted with mutations in the XP-E (DDB2) DNA repair gene. (PMID:21107348)
• Nucleotide excision repair proteins rapidly accumulate but fail to persist in human xeroderma pigmentosum XP-E (DDB2 mutant) cells. (PMID:21388382)
• Studies indicate the modular architecture of DDB1-CUL4 in complex with DDB2, CSA and CDT2 in DNA repair of UV-induced DNA lesions. (PMID:21550341)
• DDB2 subunit of UV-DDB associates transiently with the DNA-binding domain of XPC to fine-tune its engagement with CPD lesions (PMID:22039351)
• study reports a new function of DDB2 in modulating chromatin structure at DNA lesions (PMID:22492724)
• Findings indicate structural and conformational insights of the DDB1-CUL4A(DDB2) E3 ligase, with significant implications for the regulation and overall organization of the proteins responsible for initiation of nucleotide-excision repair (NER) pathway. (PMID:22822215)
• DDB2 can inhibit cell growth rate in AR-expressing cells (LNCaP) but not in AR-null cells (PC3). (PMID:22846800)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ddb2	ENSDARG00000041140
mus_musculus	Ddb2	ENSMUSG00000002109
rattus_norvegicus	Ddb2	ENSRNOG00000014071

Protein

Protein identifiers

DNA damage-binding protein 2 — Q92466 (reviewed: Q92466)

Alternative names: DDB p48 subunit, Damage-specific DNA-binding protein 2, UV-damaged DNA-binding protein 2

All UniProt accessions (6): A0A087WTQ7, A0A087WV56, A0A087WW71, A0A087WYT8, Q92466, A0A087X0X5

UniProt curated annotations — full annotation on UniProt →

Function. Protein, which is both involved in DNA repair and protein ubiquitination, as part of the UV-DDB complex and DCX (DDB1-CUL4-X-box) complexes, respectively. Core component of the UV-DDB complex (UV-damaged DNA-binding protein complex), a complex that recognizes UV-induced DNA damage and recruit proteins of the nucleotide excision repair pathway (the NER pathway) to initiate DNA repair. The UV-DDB complex preferentially binds to cyclobutane pyrimidine dimers (CPD), 6-4 photoproducts (6-4 PP), apurinic sites and short mismatches. Also functions as the substrate recognition module for the DCX (DDB2-CUL4-X-box) E3 ubiquitin-protein ligase complex DDB2-CUL4-ROC1 (also known as CUL4-DDB-ROC1 and CUL4-DDB-RBX1). The DDB2-CUL4-ROC1 complex may ubiquitinate histone H2A, histone H3 and histone H4 at sites of UV-induced DNA damage. The ubiquitination of histones may facilitate their removal from the nucleosome and promote subsequent DNA repair. The DDB2-CUL4-ROC1 complex also ubiquitinates XPC, which may enhance DNA-binding by XPC and promote NER. The DDB2-CUL4-ROC1 complex also ubiquitinates KAT7/HBO1 in response to DNA damage, leading to its degradation: recognizes KAT7/HBO1 following phosphorylation by ATR. Inhibits UV-damaged DNA repair. Inhibits UV-damaged DNA repair.

Subunit / interactions. Component of the UV-DDB complex which includes DDB1 and DDB2. The UV-DDB complex interacts with monoubiquitinated histone H2A and binds to XPC via the DDB2 subunit. Component of the DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex DDB1-CUL4-ROC1 (also known as CUL4-DDB-ROC1 and CUL4-DDB-RBX1), which includes CUL4A or CUL4B, DDB1, DDB2 and RBX1. DDB2 may function as the substrate recognition module within this complex. The DDB1-CUL4-ROC1 complex may associate with the COP9 signalosome, and this inhibits the E3 ubiquitin-protein ligase activity of the complex. A large number of other DCX complexes may also exist in which an alternate substrate targeting subunit replaces DDB2. These targeting subunits are generally known as DCAF (DDB1- and CUL4-associated factor) or CDW (CUL4-DDB1-associated WD40-repeat) proteins. Isoform D1 and isoform D2 do not interact with DDB1.

Subcellular location. Nucleus. Chromosome.

Tissue specificity. Ubiquitously expressed; with highest levels in corneal endothelium and lowest levels in brain. Isoform D1 is highly expressed in brain and heart. Isoform D2, isoform D3 and isoform D4 are weakly expressed.

Post-translational modifications. Phosphorylation by ABL1 negatively regulate UV-DDB activity. Ubiquitinated by CUL4A in response to UV irradiation. Ubiquitination appears to both impair DNA-binding and promotes ubiquitin-dependent proteolysis. Degradation of DDB2 at sites of DNA damage may be a prerequisite for their recognition by XPC and subsequent repair. CUL4A-mediated degradation appears to be promoted by ABL1. Ubiquitinated, leading to proteasomal degradation, and deubiquitinated by USP24. Deubiquitinated by USP44; leading to its stabilization on DNA lesions. Acetylated. Deacetylation by SIRT6 in response to UV stress facilitates nucleotide excision repair pathway (the NER pathway) transduction.

Disease relevance. Xeroderma pigmentosum complementation group E (XP-E) [MIM:278740] An autosomal recessive pigmentary skin disorder characterized by solar hypersensitivity of the skin, high predisposition for developing cancers on areas exposed to sunlight and, in some cases, neurological abnormalities. The skin develops marked freckling and other pigmentation abnormalities. XP-E patients show a mild phenotype with minimal or no neurologic features. The disease is caused by variants affecting the gene represented in this entry.

Domain organisation. The DWD box is required for interaction with DDB1. Interblade loops of the WD repeat region mediate most of the interaction with DNA. A hairpin between blades 5 and 6 inserts into DNA minor groove and mediates recognition of lesions and separation of the damaged and undamaged strands.

Induction. Expression is induced in response to treatment with IR or UV and this requires p53/TP53 activity.

Pathway. Protein modification; protein ubiquitination.

Similarity. Belongs to the WD repeat DDB2/WDR76 family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q92466-1	1	yes
Q92466-2	D1
Q92466-3	D2
Q92466-4	D3
Q92466-5	D4

RefSeq proteins (6): NP_000098, NP_001287663, NP_001386803, NP_001386804, NP_001386805, NP_001386807 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001680	WD40_rpt	Repeat
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR019775	WD40_repeat_CS	Conserved_site
IPR033312	DDB2	Family
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily

Pfam: PF00400

UniProt features (91 total): strand 37, mutagenesis site 11, turn 10, repeat 7, splice variant 6, helix 5, region of interest 4, modified residue 4, sequence variant 4, chain 1, short sequence motif 1, compositionally biased region 1

Structure

Experimental structures (PDB)

10 structures.

PDB	Method	Resolution (Å)
3I7L	X-RAY DIFFRACTION	2.8
4E54	X-RAY DIFFRACTION	2.85
4E5Z	X-RAY DIFFRACTION	3.22
3EI4	X-RAY DIFFRACTION	3.3
9J8W	ELECTRON MICROSCOPY	3.38
6R8Z	ELECTRON MICROSCOPY	3.9
6R91	ELECTRON MICROSCOPY	4.1
6R8Y	ELECTRON MICROSCOPY	4.3
6R90	ELECTRON MICROSCOPY	4.5
6R92	ELECTRON MICROSCOPY	4.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q92466-F1	83.69	0.70

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 24, 26, 35, 77

Mutagenesis-validated functional residues (11):

Position	Phenotype
35	decreased acetylation levels.
40	does not affect acetylation levels.
77	decreased acetylation levels.
258	impairs interaction with ddb1.
262	impairs interaction with ddb1.
264	impairs interaction with ddb1.
269	impairs interaction with ddb1.
270	impairs interaction with ddb1.
272	impairs interaction with ddb1.
273	impairs interaction with ddb1.
350	impairs interaction with ddb1.

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-5689880	Ub-specific processing proteases
R-HSA-5696394	DNA Damage Recognition in GG-NER
R-HSA-5696395	Formation of Incision Complex in GG-NER
R-HSA-5696400	Dual Incision in GG-NER
R-HSA-6796648	TP53 Regulates Transcription of DNA Repair Genes
R-HSA-8951664	Neddylation

MSigDB gene sets: 392 (showing top): REACTOME_FORMATION_OF_INCISION_COMPLEX_IN_GG_NER, E2F_Q4, E2F_Q4_01, LEE_NEURAL_CREST_STEM_CELL_DN, KANG_FLUOROURACIL_RESISTANCE_UP, MORF_RAB5A, GOBP_CELLULAR_RESPONSE_TO_UV, BASSO_B_LYMPHOCYTE_NETWORK, GOBP_CELLULAR_RESPONSE_TO_LIGHT_STIMULUS, ROVERSI_GLIOMA_COPY_NUMBER_UP, KAUFFMANN_DNA_REPAIR_GENES, GOBP_NUCLEOTIDE_EXCISION_REPAIR, E2F_Q3, CEBALLOS_TARGETS_OF_TP53_AND_MYC_DN, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN

GO Biological Process (10): protein polyubiquitination (GO:0000209), DNA repair (GO:0006281), nucleotide-excision repair (GO:0006289), pyrimidine dimer repair (GO:0006290), DNA damage response (GO:0006974), response to UV (GO:0009411), cellular response to UV (GO:0034644), protein autoubiquitination (GO:0051865), UV-damage excision repair (GO:0070914), protein ubiquitination (GO:0016567)

GO Molecular Function (5): DNA binding (GO:0003677), damaged DNA binding (GO:0003684), protein-containing complex binding (GO:0044877), ubiquitin-protein transferase activity (GO:0004842), protein binding (GO:0005515)

GO Cellular Component (10): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cell junction (GO:0030054), Cul4A-RING E3 ubiquitin ligase complex (GO:0031464), Cul4B-RING E3 ubiquitin ligase complex (GO:0031465), protein-containing complex (GO:0032991), Cul4-RING E3 ubiquitin ligase complex (GO:0080008), site of DNA damage (GO:0090734), chromosome (GO:0005694)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Global Genome Nucleotide Excision Repair (GG-NER)	3
Deubiquitination	1
Transcriptional Regulation by TP53	1
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
DNA repair	3
protein ubiquitination	2
binding	2
chromosome	2
Cul4-RING E3 ubiquitin ligase complex	2
DNA metabolic process	1
DNA damage response	1
cellular response to stress	1
response to light stimulus	1
response to UV	1
cellular response to light stimulus	1
cellular response to UV	1
protein modification by small protein conjugation	1
nucleic acid binding	1
DNA binding	1
ubiquitin-like protein transferase activity	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular_component	1
cullin-RING ubiquitin ligase complex	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

1960 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DDB2	DDB1	Q16531	999
DDB2	CUL4A	Q13619	998
DDB2	RBX1	P62877	996
DDB2	XPA	P23025	972
DDB2	RAD23B	P54727	857
DDB2	CUL4B	Q13620	846
DDB2	ERCC2	P18074	831
DDB2	CETN2	P41208	830
DDB2	DET1	Q7L5Y6	829
DDB2	USP24	Q9UPU5	820
DDB2	SMARCA4	P51532	806
DDB2	XPC	Q01831	797
DDB2	ERCC3	P19447	751
DDB2	TP53	P04637	745
DDB2	DTL	Q9NZJ0	745

IntAct

153 interactions, top by confidence:

A	B	Type	Score
DDB2	DDB1	psi-mi:“MI:0915”(physical association)	0.970
DDB1	DDB2	psi-mi:“MI:0407”(direct interaction)	0.970
DDB1	DDB2	psi-mi:“MI:0915”(physical association)	0.970
DDB2	DDB1	psi-mi:“MI:0407”(direct interaction)	0.970
CUL4B	DDB1	psi-mi:“MI:0914”(association)	0.940
DDB1	CUL4A	psi-mi:“MI:0914”(association)	0.920
COPS5	COPS2	psi-mi:“MI:0914”(association)	0.910
CUL4A	DDB2	psi-mi:“MI:0915”(physical association)	0.900
DDB2	CUL4A	psi-mi:“MI:0914”(association)	0.900
COPS2	GPS1	psi-mi:“MI:0914”(association)	0.860
COPS8	COPS2	psi-mi:“MI:0914”(association)	0.850
CUL4B	COPS2	psi-mi:“MI:0914”(association)	0.790
CUL4B	CUL4A	psi-mi:“MI:0914”(association)	0.730
COPS6	RHOBTB1	psi-mi:“MI:0914”(association)	0.730

BioGRID (515): DDB1 (Affinity Capture-Western), CUL4A (Affinity Capture-Western), CUL4B (Affinity Capture-Western), DDB2 (Biochemical Activity), CUL4A (Biochemical Activity), DDB2 (Affinity Capture-MS), DDB2 (Affinity Capture-MS), DDB2 (Affinity Capture-MS), DDB2 (Affinity Capture-MS), PFDN4 (Affinity Capture-MS), CCT3 (Affinity Capture-MS), CCT6A (Affinity Capture-MS), CUL4B (Affinity Capture-MS), CUL4A (Affinity Capture-MS), DDB1 (Affinity Capture-MS)

ESM2 similar proteins: A2AKB9, A2RRH5, A2RUS2, O43379, O60336, P58742, Q08BB3, Q0VBY8, Q148I1, Q15334, Q3MHH0, Q3SZD4, Q3U3T8, Q499N3, Q4R3J7, Q4VBE8, Q5FW06, Q5QP82, Q5RCX2, Q5T6F0, Q5U4D9, Q5U4F6, Q5VW00, Q5ZJL7, Q63ZP7, Q6AX81, Q6AY87, Q6NS57, Q6NWH1, Q6P1M3, Q6P809, Q7Z5U6, Q80Y17, Q86W42, Q8AVS9, Q8BGW4, Q8BGZ3, Q8C5V5, Q8HXL3, Q8K4K5

Diamond homologs: A1CF18, A1CQI9, A2AKB9, A5DL92, A5DST9, A8IR43, A8X8C6, A9V790, B0XM00, B2VZH2, B6GZD3, B6QC06, B8N9H4, C5PFX0, D5GBI7, F1DLK1, F4IIK6, O42860, O74184, P0CS44, P0CS45, P38959, P41318, Q0CLJ4, Q0D0X6, Q0VBY8, Q17QU5, Q28I90, Q29HG9, Q2UGK1, Q2UGU1, Q2YDS1, Q499N3, Q4VBE8, Q4WLM7, Q54D08, Q5APF0, Q5FW06, Q5I0B4, Q5QP82

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
PCSK7	down-regulates	DDB2
USP24	up-regulates	DDB2	deubiquitination
DDB2	“form complex”	DDB2/DDB1	binding
DDB2	up-regulates	E2F1	binding
ABL1	down-regulates	DDB2	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 114 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
DNA Damage Recognition in GG-NER	14	53.3×	9e-19
Prefoldin mediated transfer of substrate to CCT/TriC	7	36.8×	8e-08
Formation of TC-NER Pre-Incision Complex	13	36.7×	2e-15
RHOBTB1 GTPase cycle	5	31.7×	3e-05
Formation of tubulin folding intermediates by CCT/TriC	5	28.2×	5e-05
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding	5	27.2×	5e-05
Recognition of DNA damage by PCNA-containing replication complex	5	25.4×	7e-05
Formation of Incision Complex in GG-NER	7	23.7×	1e-06

GO biological processes:

GO term	Partners	Fold	FDR
regulation of protein neddylation	8	72.0×	1e-11
protein neddylation	9	60.8×	4e-12
positive regulation of telomere maintenance via telomerase	5	35.2×	3e-05
intrinsic apoptotic signaling pathway	5	17.2×	6e-04
cellular response to UV	6	17.1×	1e-04
protein folding	9	8.9×	6e-05
ubiquitin-dependent protein catabolic process	8	5.7×	4e-03
protein ubiquitination	14	5.6×	3e-05

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 2 cancer types — AML, BLCA.

Clinical variants and AI predictions

ClinVar

174 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	9
Likely pathogenic	5
Uncertain significance	72
Likely benign	39
Benign	26

Top pathogenic / likely-pathogenic (14)

Variant ID	HGVS	Classification
1319564	NM_000107.3(DDB2):c.574C>T (p.Arg192Ter)	Pathogenic
1333388	NM_000107.3(DDB2):c.1187C>A (p.Ser396Ter)	Pathogenic
2062799	NM_000107.3(DDB2):c.640C>T (p.Arg214Ter)	Pathogenic
3067698	NM_000107.3(DDB2):c.702+1G>T	Pathogenic
3366825	NC_000011.9:g.(47238024_47238408)_(47254511_47256123)del	Pathogenic
3711370	NM_000107.3(DDB2):c.1063C>T (p.Arg355Ter)	Pathogenic
8787	NM_000107.3(DDB2):c.730A>G (p.Lys244Glu)	Pathogenic
8789	NM_000107.3(DDB2):c.937C>T (p.Arg313Ter)	Pathogenic
8790	NM_000107.3(DDB2):c.919G>T (p.Asp307Tyr)	Pathogenic
2431840	NM_000107.3(DDB2):c.85dup (p.Glu29fs)	Likely pathogenic
2576188	NM_000107.3(DDB2):c.456+2T>C	Likely pathogenic
3599767	NM_000107.3(DDB2):c.970dup (p.Leu324fs)	Likely pathogenic
4081306	NM_000107.3(DDB2):c.880+1G>T	Likely pathogenic
872377	NM_000107.3(DDB2):c.457-2A>C	Likely pathogenic

SpliceAI

1677 predictions. Top by Δscore:

Variant	Effect	Δscore
11:47215241:G:GT	donor_gain	1.0000
11:47215244:GCTCT:G	donor_gain	1.0000
11:47215245:C:G	donor_gain	1.0000
11:47232960:G:GG	donor_gain	1.0000
11:47234570:CA:C	acceptor_loss	1.0000
11:47234571:A:AG	acceptor_gain	1.0000
11:47234572:G:GG	acceptor_gain	1.0000
11:47234572:G:GT	acceptor_loss	1.0000
11:47234572:GC:G	acceptor_gain	1.0000
11:47234572:GCA:G	acceptor_gain	1.0000
11:47234572:GCAT:G	acceptor_gain	1.0000
11:47234572:GCATC:G	acceptor_gain	1.0000
11:47234670:GAG:G	donor_gain	1.0000
11:47234673:G:GG	donor_gain	1.0000
11:47234673:G:T	donor_loss	1.0000
11:47235269:GCTT:G	acceptor_gain	1.0000
11:47235409:CAAGG:C	donor_loss	1.0000
11:47235410:AAGGT:A	donor_loss	1.0000
11:47235412:GGTG:G	donor_loss	1.0000
11:47235413:G:GA	donor_loss	1.0000
11:47235414:T:A	donor_loss	1.0000
11:47237814:T:TA	acceptor_gain	1.0000
11:47237835:A:AG	acceptor_gain	1.0000
11:47237836:G:GG	acceptor_gain	1.0000
11:47237836:GGCA:G	acceptor_gain	1.0000
11:47237953:G:T	donor_gain	1.0000
11:47237997:GTTCG:G	donor_gain	1.0000
11:47237998:T:G	donor_gain	1.0000
11:47238007:GCT:G	donor_gain	1.0000
11:47215257:GGC:G	donor_gain	0.9900

AlphaMissense

2817 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:47237843:T:A	W344R	0.997
11:47237843:T:C	W344R	0.997
11:47237877:G:C	R355P	0.997
11:47216948:T:A	W119R	0.996
11:47216948:T:C	W119R	0.996
11:47234862:T:A	W270R	0.996
11:47234862:T:C	W270R	0.996
11:47234926:T:A	V291D	0.996
11:47235327:G:C	R313P	0.995
11:47216988:A:T	K132I	0.994
11:47234838:T:C	S262P	0.994
11:47234839:C:T	S262F	0.994
11:47216984:T:C	S131P	0.993
11:47235389:T:C	F334L	0.993
11:47235391:C:A	F334L	0.993
11:47235391:C:G	F334L	0.993
11:47216976:C:A	A128D	0.992
11:47234638:G:T	G223V	0.992
11:47234839:C:A	S262Y	0.992
11:47235300:T:C	L304P	0.992
11:47216931:G:C	R113T	0.991
11:47216932:G:C	R113S	0.991
11:47216932:G:T	R113S	0.991
11:47216989:A:C	K132N	0.991
11:47216989:A:T	K132N	0.991
11:47234836:C:A	A261D	0.991
11:47238148:T:C	F400S	0.991
11:47216931:G:T	R113M	0.990
11:47234833:C:A	T260K	0.990
11:47234835:G:C	A261P	0.990

dbSNP variants (sampled 300 via entrez): RS1000400312 (11:47224284 G>C,T), RS1000547724 (11:47231151 A>C), RS1000796690 (11:47230361 C>T), RS1000848691 (11:47224532 G>A,C), RS1001044620 (11:47237149 G>C), RS1001143751 (11:47222951 G>A), RS1001195558 (11:47214174 C>G,T), RS1001226693 (11:47213455 G>A), RS1001343139 (11:47224897 T>G), RS1001467664 (11:47227734 A>G), RS1001498614 (11:47227407 A>G), RS1001513565 (11:47216036 G>GTTC), RS1001671776 (11:47220692 T>C), RS1001804565 (11:47226126 A>G), RS1001957754 (11:47221685 T>C)

Disease associations

OMIM: gene MIM:600811 | disease phenotypes: MIM:278740, MIM:278700, MIM:167000

GenCC curated gene-disease

Disease	Classification	Inheritance
xeroderma pigmentosum group E	Definitive	Autosomal recessive
xeroderma pigmentosum	Supportive	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
xeroderma pigmentosum group E	Definitive	AR

Mondo (3): xeroderma pigmentosum group E (MONDO:0010213), xeroderma pigmentosum (MONDO:0019600), ovarian cancer (MONDO:0008170)

Orphanet (3): Xeroderma pigmentosum (Orphanet:910), Rare ovarian cancer (Orphanet:213500), OBSOLETE: Xeroderma pigmentosum complementation group E (Orphanet:276261)

HPO phenotypes

64 total (30 of 64 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000028	Cryptorchidism
HP:0000135	Hypogonadism
HP:0000164	Abnormality of the dentition
HP:0000252	Microcephaly
HP:0000365	Hearing impairment
HP:0000407	Sensorineural hearing impairment
HP:0000486	Strabismus
HP:0000491	Keratitis
HP:0000498	Blepharitis
HP:0000509	Conjunctivitis
HP:0000518	Cataract
HP:0000524	Conjunctival telangiectasia
HP:0000613	Photophobia
HP:0000621	Entropion
HP:0000648	Optic atrophy
HP:0000656	Ectropion
HP:0000958	Dry skin
HP:0000962	Hyperkeratosis
HP:0000963	Thin skin
HP:0000992	Cutaneous photosensitivity
HP:0000995	Melanocytic nevus
HP:0001009	Telangiectasia
HP:0001029	Poikiloderma
HP:0001034	Hypermelanotic macule
HP:0001053	Hypopigmented skin patches
HP:0001059	Pterygium
HP:0001072	Thickened skin
HP:0001249	Intellectual disability
HP:0001250	Seizure

GWAS associations

12 associations (top):

Study	Trait	p-value
GCST002329_2	Acne (severe)	4.000000e-09
GCST004521_165	Autism spectrum disorder or schizophrenia	3.000000e-08
GCST005232_56	Neuroticism	1.000000e-16
GCST006940_125	Neurociticism	4.000000e-10
GCST006942_9	Feeling lonely	2.000000e-09
GCST006943_11	Feeling miserable	6.000000e-10
GCST007825_4	Alzheimer’s disease or fasting glucose levels (pleiotropy)	3.000000e-16
GCST010002_238	Refractive error	2.000000e-14
GCST010244_64	Triglyceride levels	2.000000e-31
GCST011348_26	High density lipoprotein cholesterol levels	1.000000e-08
GCST90002389_462	Lymphocyte percentage of white cells	2.000000e-13
GCST90002394_465	Monocyte percentage of white cells	2.000000e-19

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0007660	neuroticism measurement
EFO:0007865	loneliness measurement
EFO:0009598	feeling miserable measurement
EFO:0004530	triglyceride measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0007989	monocyte percentage of leukocytes

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D010051	Ovarian Neoplasms	C04.588.322.455; C12.050.351.500.056.630.705; C12.050.351.937.418.685; C12.100.250.056.630.705; C12.900.418.685; C19.344.410; C19.391.630.705
D014983	Xeroderma Pigmentosum	C04.834.867; C16.131.831.936; C16.320.850.970; C17.800.600.925; C17.800.621.936; C17.800.804.936; C17.800.827.970; C18.452.284.975
C564732	Xeroderma Pigmentosum, Complementation Group E (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

108 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects expression, affects cotreatment, increases expression	12
sodium arsenite	increases abundance, affects expression, affects cotreatment, decreases expression	10
Cisplatin	affects expression, increases expression, affects cotreatment, decreases expression	7
Aflatoxin B1	affects expression, affects cotreatment, increases expression	7
Cadmium Chloride	decreases expression, increases expression	6
Arsenic	affects methylation, decreases expression, affects cotreatment, increases abundance	4
Fluorouracil	affects response to substance, increases expression, increases reaction	4
Tobacco Smoke Pollution	affects expression, decreases expression, increases expression	4
Valproic Acid	affects expression, decreases expression	4
Cyclosporine	decreases expression, increases expression	4
Resveratrol	affects cotreatment, increases expression	3
bisphenol A	affects expression, decreases expression	2
trichostatin A	affects cotreatment, decreases expression	2
dibenzo(a,l)pyrene	increases expression	2
pifithrin	decreases reaction, increases expression	2
monomethylarsonous acid	decreases expression	2
Estradiol	decreases expression, increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression	2
Particulate Matter	decreases expression, increases abundance	2
aristolochic acid I	increases expression	1
6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine	increases expression	1
FR900359	increases phosphorylation	1
TAK-243	increases sumoylation	1
pradimicin-IRD	decreases expression, affects expression, affects response to substance	1
benzo(b)fluoranthene	affects cotreatment, increases expression	1
deoxynivalenol	increases expression	1
VX-agent	increases expression	1
Nonidet P-40	decreases expression	1
decabromobiphenyl ether	decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1

Cellosaurus cell lines

20 cell lines: 11 finite cell line, 5 cancer cell line, 3 transformed cell line, 1 telomerase immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_7327	GM01646	Transformed cell line	Female
CVCL_B1PV	Abcam HeLa DDB2 KO	Cancer cell line	Female
CVCL_B8EK	Abcam HCT 116 DDB2 KO	Cancer cell line	Male
CVCL_B8UN	Abcam MCF-7 DDB2 KO	Cancer cell line	Female
CVCL_B9GT	Abcam A-549 DDB2 KO	Cancer cell line	Male
CVCL_F028	GM01389	Finite cell line	Female
CVCL_F496	XP2RO	Finite cell line	Female
CVCL_F497	XP3RO LCL	Transformed cell line	Female
CVCL_KT50	HeLa SilenciX DDB2	Cancer cell line	Female
CVCL_M225	CW3-XPE	Transformed cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00190697	PHASE4	COMPLETED	A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00727961	PHASE4	COMPLETED	A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)
NCT00740116	PHASE4	COMPLETED	Tranexamic Acid in Surgery of Advanced Ovarian Cancer
NCT00817479	PHASE4	COMPLETED	Tumor Gene Expression in Women With Ovarian Cancer
NCT01432015	PHASE4	COMPLETED	Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
NCT01706120	PHASE4	UNKNOWN	Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab
NCT01932125	PHASE4	COMPLETED	An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
NCT01953107	PHASE4	COMPLETED	Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.
NCT02035345	PHASE4	TERMINATED	Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
NCT02243059	PHASE4	WITHDRAWN	Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer
NCT03164980	PHASE4	TERMINATED	QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer
NCT03384511	PHASE4	COMPLETED	The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
NCT03543462	PHASE4	COMPLETED	Diaphragmatic Resection And Gynecological Ovarian Neoplasm
NCT03752216	PHASE4	COMPLETED	NIraparib and Quality of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib.
NCT03858166	PHASE4	TERMINATED	Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer
NCT04024254	PHASE4	COMPLETED	A Study of Serum Folate Levels in Patients Treated With Olaparib
NCT04330040	PHASE4	COMPLETED	Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
NCT04352439	PHASE4	COMPLETED	Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT05187208	PHASE4	UNKNOWN	PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
NCT05606692	PHASE4	RECRUITING	Influences of Propofol and Sevoflurane Anesthesia in Ovarian Cancer (Anesthetics)
NCT05926336	PHASE4	RECRUITING	The Effects of Using Different Anesthetics on the Prognosis of Primary Tumors and Its Mechanism of Action
NCT06412120	PHASE4	RECRUITING	Study Evaluating Safety, Tolerability, and Metabolism of Niraparib
NCT06871787	PHASE4	NOT_YET_RECRUITING	Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery
NCT06887933	PHASE4	NOT_YET_RECRUITING	A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer
NCT07469202	PHASE4	NOT_YET_RECRUITING	CYTALUX Dose Extension Study
NCT00001806	PHASE3	COMPLETED	Methods in Education for Breast Cancer Genetics
NCT00002477	PHASE3	UNKNOWN	Adjuvant Chemotherapy Compared With Observation in Treating Patients With Resected Early Stage Ovarian Epithelial Cancer
NCT00002568	PHASE3	COMPLETED	Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer
NCT00002641	PHASE3	COMPLETED	Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
NCT00002717	PHASE3	COMPLETED	Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
NCT00002764	PHASE3	COMPLETED	Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
NCT00002819	PHASE3	TERMINATED	Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
NCT00002894	PHASE3	COMPLETED	Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer
NCT00002895	PHASE3	COMPLETED	Early Chemotherapy Based on CA 125 Level Alone Compared With Delayed Chemotherapy in Treating Patients With Recurrent Ovarian Epithelial , Fallopian Tube, or Primary Peritoneal Cancer
NCT00003120	PHASE3	COMPLETED	S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
NCT00003214	PHASE3	COMPLETED	Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer
NCT00003322	PHASE3	COMPLETED	Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer
NCT00003636	PHASE3	COMPLETED	Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00003644	PHASE3	COMPLETED	Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer